Literature DB >> 1727374

Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain.

E M Cornford1, D Young, J W Paxton, G J Finlay, W R Wilson, W M Pardridge.   

Abstract

Melphalan, a nitrogen mustard derivative of the neutral amino acid L-phenylalanine, was transported across the rat blood-brain barrier by the large (L-system) neutral amino acid transporter in tumor-bearing brain, but no evidence for blood-brain barrier transport by the alanine-serine-cysteine system carrier was obtained in the present study. The ability of melphalan to inhibit phenylalanine uptake was compared in rats implanted with two experimental CNS tumors: the C-6 glioma (a model of primary brain tumors) and Walker carcinoma (a model of metastatic brain tumors). The melphalan concentration which caused 50% inhibition of blood-brain barrier (BBB) phenylalanine uptake (Ki) was 0.49 +/- 0.18 mM in the Walker tumor, compared with 0.46 +/- 0.19 mM in the contralateral control brain. In the ipsilateral hemisphere (Ki = 0.59 +/- 0.25 mM) and contralateral hemisphere (Ki = 0.45 +/- 0.19 mM), drug entry was also via the neutral amino acid transporter. In C-6 gliomas (Ki = 0.77 +/- 0.20 mM) and contralateral control brain (Ki = 0.84 +/- 0.29 mM), melphalan also inhibited BBB phenylalanine transport. A major finding was that, at melphalan concentrations greater than 1.0 mM, BBB permeability of radiolabeled indium (chelated to EDTA) increased in proportion to melphalan concentration. In the contralateral hemisphere of rats implanted with C-6 gliomas, brain extractions of indium-EDTA measured 3 to 4% in the absence of drug, 5 to 6% at 2.5 mM melphalan, and 9 to 10% at 5 mM melphalan. A similar phenomenon was observed in the nontumoral brain regions of rats implanted with Walker carcinoma cells. In normal (nonimplanted) rats, melphalan's inhibition (Ki = 0.29 mM) of phenylalanine and tryptophan (Ki = 0.20 mM) uptake was confirmed, and brain extraction of sucrose (a nonspecific marker which does not penetrate the intact BBB) was observed to increase in proportion to melphalan concentration. We conclude that melphalan not only enters the brain via the neutral amino acid transporter, but at higher concentrations (greater than 1 mM) may open the blood-brain barrier in a nonspecific manner.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727374

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

Review 2.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 3.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  Drug transport across the blood-brain barrier.

Authors:  William M Pardridge
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-29       Impact factor: 6.200

5.  Relational graph convolutional networks for predicting blood-brain barrier penetration of drug molecules.

Authors:  Yan Ding; Xiaoqian Jiang; Yejin Kim
Journal:  Bioinformatics       Date:  2022-05-13       Impact factor: 6.931

6.  LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.

Authors:  Arik A Zur; Huan-Chieh Chien; Evan Augustyn; Andrew Flint; Nathan Heeren; Karissa Finke; Christopher Hernandez; Logan Hansen; Sydney Miller; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2016-09-03       Impact factor: 2.823

Review 7.  Progress and problems in the application of focused ultrasound for blood-brain barrier disruption.

Authors:  Natalia Vykhodtseva; Nathan McDannold; Kullervo Hynynen
Journal:  Ultrasonics       Date:  2008-04-14       Impact factor: 2.890

8.  The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft.

Authors:  J N Rich; G B Elion; D Wellner; O M Colvin; D R Groothuis; J H Hilton; K E Schlageter; D D Bigner; O W Griffith; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  The Effects of Prodrug Size and a Carbonyl Linker on l-Type Amino Acid Transporter 1-Targeted Cellular and Brain Uptake.

Authors:  Brooklynn Venteicher; Kasey Merklin; Huy X Ngo; Huan-Chieh Chien; Keino Hutchinson; Jerome Campbell; Hannah Way; Joseph Griffith; Cesar Alvarado; Surabhi Chandra; Evan Hill; Avner Schlessinger; Allen A Thomas
Journal:  ChemMedChem       Date:  2020-12-11       Impact factor: 3.466

10.  Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours.

Authors:  Kate M Lewis; Elizabeth Harford-Wright; Robert Vink; Mounir N Ghabriel
Journal:  Cancer Cell Int       Date:  2013-02-01       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.